Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 04, 2022

SELL
$7.81 - $20.45 $2.01 Million - $5.26 Million
-257,110 Closed
0 $0
Q4 2021

Feb 10, 2022

SELL
$15.2 - $35.51 $390,761 - $912,891
-25,708 Reduced 9.09%
257,110 $4.89 Million
Q3 2021

Nov 10, 2021

SELL
$21.78 - $40.45 $30,143 - $55,982
-1,384 Reduced 0.49%
282,818 $9.41 Million
Q2 2021

Aug 13, 2021

SELL
$32.5 - $48.96 $317,395 - $478,143
-9,766 Reduced 3.32%
284,202 $11 Million
Q1 2021

May 14, 2021

BUY
$41.61 - $54.3 $786,637 - $1.03 Million
18,905 Added 6.87%
293,968 $14.2 Million
Q4 2020

Feb 02, 2021

BUY
$25.27 - $54.9 $546,084 - $1.19 Million
21,610 Added 8.53%
275,063 $14.3 Million
Q3 2020

Nov 05, 2020

BUY
$18.49 - $27.24 $696,573 - $1.03 Million
37,673 Added 17.46%
253,453 $6.78 Million
Q2 2020

Aug 12, 2020

BUY
$8.9 - $21.84 $209,853 - $514,965
23,579 Added 12.27%
215,780 $4.2 Million
Q1 2020

May 12, 2020

BUY
$7.14 - $15.99 $88,536 - $198,276
12,400 Added 6.9%
192,201 $1.89 Million
Q4 2019

Jan 27, 2020

BUY
$5.1 - $11.2 $362,105 - $795,211
71,001 Added 65.26%
179,801 $2 Million
Q3 2019

Oct 31, 2019

BUY
$5.38 - $8.99 $109,214 - $182,497
20,300 Added 22.94%
108,800 $611,000
Q2 2019

Aug 15, 2019

BUY
$6.27 - $8.65 $21,945 - $30,275
3,500 Added 4.12%
88,500 $766,000
Q1 2019

May 03, 2019

SELL
$4.02 - $8.04 $46,254 - $92,508
-11,506 Reduced 11.92%
85,000 $683,000
Q3 2018

Nov 13, 2018

BUY
$5.15 - $14.0 $20,115 - $54,684
3,906 Added 4.22%
96,506 $540,000
Q2 2018

Aug 15, 2018

SELL
$12.5 - $15.0 $172,500 - $207,000
-13,800 Reduced 12.97%
92,600 $1.22 Million
Q3 2017

Nov 15, 2017

BUY
$10.0 - $12.7 $1.06 Million - $1.35 Million
106,400
106,400 $1.26 Million

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.29B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.